Dopamine receptors genes polymorphisms in Parkinson patients with levodopa-induced dyskinesia

Pozhidaev, I., Alifirova, V. M., Freidin, M. B., Zhukova, I. A., Fedorenko, O. Y., Osmanova, D. Z., Mironova, Y. S., Wilffert, B., Ivanova, S. A. & Loonen, A. J. M., 1-Oct-2017, In : European Neuropsychopharmacology. 27, Supplement 4, p. S590 1 p.

Research output: Contribution to journalMeeting AbstractAcademic

Copy link to clipboard


  • Dopamine receptors genes polymorphisms in Parkinson patients with levodopa-induced dyskinesia

    Final publisher's version, 67 KB, PDF document

    Request copy


  • I. Pozhidaev
  • V.M. Alifirova
  • M.B. Freidin
  • I.A. Zhukova
  • O.Y. Fedorenko
  • D.Z. Osmanova
  • Y.S. Mironova
  • B. Wilffert
  • S.A. Ivanova
  • A.J.M. Loonen
Introduction: Long-term levodopa treatment of Parkinson's disease (PD) is frequently complicated by spontaneously occur ring involuntary muscle movements called levodopa-induced dyskinesia (LID). LID are a substantial barrier to effective symptomatic management of Parkinson's disease (PD), as up to 45% of L-DOPA users develop LID within 5 years [1]. The exact pathological mechanism of this complication has not yet been elucidated. A lot of studies nowadays which approved complex genetic nature of LID. And these genes are involved not only for oxidative stress, but in drug metabolism too [2-4]. Objective: This study aimed to investigate a possible contribution of polymorphic variants of DRD1, DRD2, DRD2/ANKK1, DRD3, DRD4 genes in the development of LID in PD patients. Methods: 212 patients with Parkinson's disease on levodopa therapy were investigated. Dyskinesia was measured by using Abnormal Involuntary Movement Scale (AIMS). DNA extraction and fluorogenic 5'-exonuclease TaqMan genotyping assays were conducted according to standard protocols and blind to clinical status of the subjects. Genotyping was carried out on 28 SNPs of dopamine receptors (rs4532, rs936461, rs6275, rs1801028, rs4245147, rs134655, rs6277, rs1076560, rs2283265, rs179997, rs6279, rs1076562, rs2734842, rs2734849, rs11721264, rs167770, rs3773678, rs963468, rs7633291, rs2134655, rs9817063, rs324035, rs1800828, rs167771, rs6280, rs1587756, rs3758653, rs11246226) on the MassARRAY® Analyzer 4 (Agena Bioscience™) using the set SEQUENOM Consumables iPLEX Gold 384. SPSS sof tware was used for statistical analysis. Statistical significance of the association testing was established using permutations. P-value
Original languageEnglish
Pages (from-to)S590
Number of pages1
JournalEuropean Neuropsychopharmacology
Issue numberSupplement 4
Publication statusPublished - 1-Oct-2017


  • biological marker, dopamine 2 receptor, dopamine 3 receptor, dopamine 4 receptor, endogenous compound, levodopa, phosphodiesterase I, Abnormal Involuntary Movement Scale, adult, adverse event, analyzer, cohort analysis, data analysis software, DNA extraction, drug metabolism, drug therapy, female, gender, gene frequency, gene mutation, genetic marker, genetic susceptibility, genotype, human, levodopa-induced dyskinesia, major clinical study, male, onset age, oxidative stress, Parkinson disease, phenotype, single nucleotide polymorphism, statistical significance, treatment response, visually impaired person

View graph of relations

ID: 50417802